{"id":"W3186399416","doi":"10.1158/1078-0432.ccr-21-1059","title":"Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; bluebird bio; Agios Pharmaceuticals; TG Therapeutics; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Gilead Sciences; Sanofi; Legend Biotech; Celgene; AstraZeneca; Pfizer; Amgen; GlaxoSmithKline; Multiple Myeloma Research Foundation; Foundation for the National Institutes of Health","keywords":"Multiple myeloma; Medicine; Drug; Residual; Intensive care medicine; Minimal residual disease; Disease; Internal medicine; Pharmacology; Computer science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0485017,0.0008182232,0.003018912,0.004678402,0.0009239989,0.009201116,0.003410433,0.004302355,0.03012416],"category_scores_gemma":[0.1423935,0.0004722333,0.002204304,0.007431446,0.002485133,0.008284708,0.005618251,0.006555083,0.01092182],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005029471,"about_ca_system_score_gemma":0.01428982,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002880213,"about_ca_topic_score_gemma":0.003494912,"domain_scores_codex":[0.9711013,0.01571962,0.004381781,0.001622366,0.006168286,0.001006702],"domain_scores_gemma":[0.9112222,0.03294596,0.01223926,0.008328512,0.02431146,0.01095269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0005046807,0.00009675527,0.002490054,0.002422706,0.0001102091,0.00007307658,0.00008560874,0.0006773575,0.0001947895,0.0343143,0.2648723,0.6941581],"study_design_scores_gemma":[0.000343714,0.0003961523,0.006986823,0.00698344,0.0001651186,0.0003117077,0.0001733977,0.00221159,0.0002510759,0.04265479,0.9394424,0.00007992172],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.005464804,0.2984206,0.03350904,0.38885,0.03449084,0.002659547,0.0125911,0.002282961,0.2217312],"genre_scores_gemma":[0.2322973,0.3787937,0.1267562,0.1049467,0.06042521,0.007946484,0.03057205,0.001736037,0.05652644],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0485017,"threshold_uncertainty_score":0.2565046,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3248483922535994,"score_gpt":0.5827453539241509,"score_spread":0.2578969616705515,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}